Ernexa Therapeutics Inc.
ERNA
$6.80
-$0.59-7.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 1.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 1.00K |
| Cost of Revenue | -- | -- | -- | -- | 0.00 |
| Gross Profit | -- | -- | -- | -- | 1.00K |
| SG&A Expenses | 1.42M | 958.00K | 1.37M | 1.42M | 1.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.09M | 1.99M | 2.50M | 2.73M | 2.70M |
| Operating Income | -2.09M | -1.99M | -2.50M | -2.73M | -2.70M |
| Income Before Tax | -1.56M | -1.23M | -3.14M | -8.19M | -5.75M |
| Income Tax Expenses | -62.00K | 6.00K | 3.00K | 8.00K | 11.00K |
| Earnings from Continuing Operations | -1.50M | -1.24M | -3.14M | -8.20M | -5.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.50M | -1.24M | -3.14M | -8.20M | -5.76M |
| EBIT | -2.09M | -1.99M | -2.50M | -2.73M | -2.70M |
| EBITDA | -2.08M | -1.98M | -2.48M | -2.71M | -2.68M |
| EPS Basic | -4.57 | -3.77 | -15.19 | -57.64 | -56.38 |
| Normalized Basic EPS | -3.02 | -3.74 | -9.46 | -35.99 | -41.34 |
| EPS Diluted | -4.57 | -3.77 | -15.19 | -57.64 | -56.38 |
| Normalized Diluted EPS | -3.02 | -3.74 | -9.46 | -35.99 | -41.34 |
| Average Basic Shares Outstanding | 330.30K | 329.00K | 207.20K | 142.30K | 102.30K |
| Average Diluted Shares Outstanding | 330.30K | 329.00K | 207.20K | 142.30K | 102.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |